Debt-to-equity of C4 Therapeutics, Inc. from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
C4 Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 30 Sep 2025.
  • C4 Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 66%, a 23% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

C4 Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 66% +12% +23% 30 Sep 2025
Q2 2025 62% +8% +15% 30 Jun 2025
Q1 2025 58% +3% +5.3% 31 Mar 2025
Q4 2024 56% +2% +3% 31 Dec 2024
Q3 2024 54% +1% +1.6% 30 Sep 2024
Q2 2024 54% +3% +6.3% 30 Jun 2024
Q1 2024 55% +9% +19% 31 Mar 2024
Q4 2023 54% +10% +23% 31 Dec 2023
Q3 2023 53% +14% +35% 30 Sep 2023
Q2 2023 51% +16% +45% 30 Jun 2023
Q1 2023 47% +15% +50% 31 Mar 2023
Q4 2022 44% +14% +45% 31 Dec 2022
Q3 2022 39% +6% +19% 30 Sep 2022
Q2 2022 35% -23% -40% 30 Jun 2022
Q1 2022 31% 31 Mar 2022
Q4 2021 31% 31 Dec 2021
Q3 2021 33% 30 Sep 2021
Q2 2021 58% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.